Qiagen downgraded to Neutral from Outperform at Baird

Baird downgraded Qiagen (QGEN) to Neutral from Outperform with a price target of $42, down from $52. The firm has concerns around the future of National Institutes of Health funding, particularly after surveying academic researchers last week. Given these uncertainties and sentiment overhang, it downgrades the shares. While the stock has pulled back significantly since the Trump inauguration, Baird has “trouble seeing what gets sentiment working again absent some sort of resolution,” the analyst tells investors in a research note.